###begin article-title 0
###xml 29 37 <span type="species:ncbi:9606">patients</span>
HLA-DR and HLA-DQ alleles in patients from the south of Brazil: markers for leprosy susceptibility and resistance
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 152 161 152 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. leprae</italic>
###xml 152 161 <span type="species:ncbi:1769">M. leprae</span>
Many epidemiological studies have shown that the genetic factors of the host play a role in the variability of clinical response to infection caused by M. leprae. With the purpose of identifying genes of susceptibility, the present study investigated the possible role of HLA-DRB1 and DQA1/DQB1 alleles in susceptibility to leprosy, and whether they account for the heterogeneity in immune responses observed following infection in a Southern Brazilian population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 238 241 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
One hundred and sixty-nine leprosy patients and 217 healthy controls were analyzed by polymerase chain reaction amplification and reverse hybridization with sequence-specific oligonucleotide probes and sequence-specific primers(One Lambda(R), CA, USA).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 92 94 92 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 102 104 102 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 265 267 265 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 276 278 276 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 361 363 361 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 371 373 371 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 434 436 434 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 444 446 444 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 504 505 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 602 604 602 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 612 614 612 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 765 767 765 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 775 777 775 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
There was a positive association of HLA-DRB1*16 (*1601 and *1602) with leprosy per se (7.3% vs. 3.2%, P = 0.01, OR = 2.52, CI = 1.26-5.01), in accord with previous serological studies, which showed DR2 as a marker of leprosy. Although, HLA-DQA1*05 frequency (29.8% vs. 20.9%, P = 0.0424, OR = 1.61, CI = 1.09-2.39) was higher in patients, and HLA-DQA1*02 (3.0% vs. 7.5%, P = 0.0392, OR = 0.39, CI = 0.16 - 0.95) and HLA-DQA1*04 (4.0% vs. 9.1%, P = 0.0314, OR = 0.42, CI = 0.19 - 0.93) frequencies lower, P-values were not significant after the Bonferroni's correction. Furthermore, HLA-DRB1*1601 (9.0% vs. 1.8%; P = 0.0016; OR = 5.81; CI = 2.05-16.46) was associated with susceptibility to borderline leprosy compared to control group, and while HLA-DRB1*08 (11.2% vs. 1.2%; P = 0.0037; OR = 12.00; CI = 1.51 - 95.12) was associated with susceptibility to lepromatous leprosy, when compared to tuberculoid leprosy, DRB1*04 was associated to protection.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
These data confirm the positive association of HLA-DR2 (DRB1*16) with leprosy per se, and the protector effect of DRB1*04 against lepromatous leprosy in Brazilian patients.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 77 98 77 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium leprae </italic>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 77 97 <span type="species:ncbi:1769">Mycobacterium leprae</span>
Leprosy is a chronic infectious disease caused by the intracellular pathogen Mycobacterium leprae [1], whose clinical manifestations are largely confined to the skin and peripheral nervous system [2].
###end p 11
###begin p 12
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
Although the global prevalence of leprosy has dropped dramatically, coinciding with the introduction of multiple-drug therapy, new-case detection rates have remained stable over the years at approximately 500,000 new cases per year. The majority of the remaining leprosy cases are found in India and a few other countries, including Brazil [3].
###end p 12
###begin p 13
###xml 226 236 226 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. leprae </italic>
###xml 255 264 255 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 268 275 268 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 646 647 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 226 235 <span type="species:ncbi:1769">M. leprae</span>
Considered a multifactorial disease, the expression of clinical manifestations of leprosy reflects the relationship between the host and the parasite. There is a strong correlation between cell-mediated immunity (CMI) against M. leprae antigens, observed in vitro and in vivo, and the clinical course of the disease. There are five clinical forms of the disease, ranging between two poles: tuberculoid (TT) and lepromatous (LL) leprosy. Tuberculoid leprosy is the result of high cell-mediated immunity, with a largely Th1-type immune response, and lepromatous leprosy is characterized by low cell-mediated immunity with a humoral Th2 response [2,4].
###end p 13
###begin p 14
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 226 242 226 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. tuberculosis </italic>
###xml 246 255 246 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. leprae</italic>
###xml 682 683 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 226 241 <span type="species:ncbi:1773">M. tuberculosis</span>
###xml 246 255 <span type="species:ncbi:1769">M. leprae</span>
Many epidemiological studies, which had the objective of identifying genes of susceptibility [5], have shown that the genetic factors of the host play a role in the variability of clinical response to infection caused by both M. tuberculosis and M. leprae. The Major Histocompatibility Complex (MHC), located on chromosome 6p21, is the most polymorphic genetic system in mammalians, and has been studied with regard to a wide variety of diseases of distinct etiology, including infectious diseases. The fundamental role of the different molecules within the MHC is antigen processing and presentation to the T-cell receptor (TCR), which is crucial for the cell interactions in CMI [6].
###end p 14
###begin p 15
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loci</italic>
###xml 178 187 178 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. leprae</italic>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loci</italic>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 178 187 <span type="species:ncbi:1769">M. leprae</span>
In humans, while the classic class I loci, HLA-A, -B, and -C, bind peptides of intra-cellular origin and present them to CD8+T cells, resulting in the death of cells infected by M. leprae, the classic class II loci, HLA-DR, -DQ, and -DP, primarily bind peptides of extra-cellular origin and present them to CD4+T cells, resulting in cytokine production and T-cell help in antibody production.
###end p 15
###begin p 16
###xml 192 199 192 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
While the idea of HLA-related genes being involved in the control of the clinical progression of leprosy is well documented, the possible role of the HLA region in susceptibility to infection per se has also been suggested [7]. Some results have already been found for class I HLA alleles [8], however a greater number of studies have reported increased frequencies of class II alleles in TT and LL patients in several populations [9-14].
###end p 16
###begin p 17
The aims of this study were to determine which HLA class II polymorphisms affect differential susceptibility to leprosy and whether these account for the heterogeneity in immune responses observed following infection in a Southern Brazilian population.
###end p 17
###begin title 18
Methods
###end title 18
###begin title 19
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 19
###begin p 20
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 512 520 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
One hundred and sixty-nine (169) leprosy patients attended in the 15a Regional de Saude da Secretaria de Saude, Parana State, Southern Brazil, took part in this study. All the patients were residents in the cities of Maringa, Sarandi and Umuarama, and the surrounding region, in Parana state. They were classified into four distinct groups according to clinical and laboratorial (Mitsuda's test and histology exams) observations made by the dermatologist responsible for leprosy diagnosis: TT (41 out of the 169 patients, 24.3%), LL (63 patients, 37.3%), Borderline (49 patients, 29.0%), and Indeterminate (4 patients, 2.4%).
###end p 20
###begin p 21
###xml 205 207 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 147 153 <span type="species:ncbi:9606">person</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
Patient ages at the time of sample collection varied between 22 and 93 years (mean, 52.8; +/- SD, 14.6). However, leprosy is traditionally a young person's disease, with a median age at onset of 35 years [15]. Seventy-two (42.6%) of the patients were female and 97 (57.4%) male.
###end p 21
###begin p 22
###xml 227 230 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The control group was composed of 217 healthy individuals, selected according to age, sex, ethnic group, occupation and other demographic parameters, with no history of HLA-associated diseases (hepatitis, auto-immune diseases, HIV and tuberculosis). They were typified by the Laboratorio de Imunogenetica of the Universidade Estadual de Maringa. Their ages varied from 20 to 58 years (mean, 42.0; SD, 7.1), and 106 (48.8%) were female and 111 (51.2%) male.
###end p 22
###begin p 23
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
The population of Parana is predominantly of European origin (80.6%), with a small but significant contribution of African (12.5%) and Amerindian (7.0%) genes [16]. Both the patients and healthy controls were classified as mixed ethnic groups, according to phenotypic characteristics, because according to Parra et al. (2003) [17], in Brazil, at an individual level, skin color determined by physical evaluation is a poor predictor of genomic African ancestry.
###end p 23
###begin p 24
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
The risk of population stratification bias, due to differences in ethnic background between patients and controls, and variations of allele frequencies, according to ethnic background, were minimized by matching patients with control individuals of the same ethnic background, mean age, gender rates and residence in the same geographical areas of leprosy prevalence.
###end p 24
###begin p 25
###xml 8 20 <span type="species:ncbi:9606">participants</span>
###xml 158 163 <span type="species:ncbi:9606">Human</span>
All the participants signed written informed-consent forms, authorizing the use of their samples in the study, which was approved by the Ethics Committee for Human Research at the Universidade Estadual de Maringa.
###end p 25
###begin title 26
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
Determination of HLA class II alleles
###end title 26
###begin p 27
###xml 267 270 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Blood samples (10 mL) were collected from the subjects in tubes containing anticoagulant (EDTA) and centrifuged at 2,500 rpm for 15 minutes, and the Buffy-coat was conserved at -20degreesC until use. The genomic DNA was extracted by EZ-DNA kits (Biological Industries(R), Kibbutz Beit Haemek, Israel) from 150 muL of frozen blood, and then stored at -20degreesC.
###end p 27
###begin p 28
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 352 355 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 409 412 407 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 525 530 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">loci </italic>
HLA class II alleles for DRB1* (alleles 01-16), DQA1* (alleles 01-06) and DQB1* (alleles 02-06) were genotyped by combining PCR-SSP (polymerase chain reaction - sequence-specific primers), using the HLA genotyping kit [18] with modifications [19] and/or PCR-SSO (polymerase chain reaction - sequence-specific oligonucleotides) using Luminex (One Lambda(R), CA, USA). High resolution PCR-SSP typing (One Lambda(R), CA, USA) was also used to define the DRB1*04 (0401-0463) and HLA-DRB1*16 (alleles 1601-1608) alleles, as these loci are associated with leprosy.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Allele frequency was obtained through direct counting of the alleles. The allele-frequency distributions were confirmed as being in Hardy-Weinberg equilibrium by calculating the expected frequencies of the genotypes and comparing them to the observed values using Arlequin software, version 3.1 [20], available at .
###end p 30
###begin p 31
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 363 365 363 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 462 464 462 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The analysis of the associations between the HLA variables and the occurrence of leprosy per se and the LL and TT subgroups, was performed using the Chi square test, with the Yates's correction or Fisher's Exact Test when necessary, using the Graph Pad Software program (San Diego, CA, USA), available at . Data were considered statistically significant when the P value was less than or equal to 0.05. However, to account for multiple comparisons, the observed P values were corrected (pc) for the number of alleles when one locus was considered alone.
###end p 31
###begin p 32
The odds ratios (OR), with 95% confidence intervals (95% CI), were calculated using SISA statistics online , to evaluate the risk of the individual developing the disease while having a particular HLA type.
###end p 32
###begin title 33
Results
###end title 33
###begin p 34
###xml 223 231 <span type="species:ncbi:9606">patients</span>
The possibility of an association between class II HLA alleles and leprosy in a population from the south of Brazil was investigated in this study through the comparison of the HLA-DRB1, DQA1 and DQB1 allele frequencies of patients suffering the disease with those of a healthy control group.
###end p 34
###begin title 35
###xml 8 17 8 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se vs</italic>
Leprosy per se vs. control group
###end title 35
###begin p 36
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 162 169 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 277 279 277 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 287 289 287 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 406 408 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 416 418 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 458 460 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 469 471 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 599 601 599 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 609 611 609 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 679 681 679 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 688 690 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 824 831 824 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 838 840 838 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 849 851 849 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
The HLA-DRB1 and DQA1\DQB1 allele frequencies of the patients and control group are shown in Tables 1 and 2, respectively. There were differences between leprosy per se patients and the control group for HLA-DRB1*16, which appeared with greater frequency in the patients (7.3% vs. 3.2%, P = 0.01, OR = 2.52, CI = 1.26-5.01, pc = 0.13). Among the DRB1*16 alleles, DRB1*1602 had the greatest frequency (3.3% vs. 1.1%, P = 0.0684). HLA-DQA1*05 frequency (29.8% vs. 20.9%, P = 0.0424, OR = 1.61, CI = 1.09-2.39, pc = 0.4664) was higher in patients compared to the control group, while HLA-DQA1*02 (3.0% vs. 7.5%, P = 0.0392, OR = 0.39, CI = 0.16-0.95, pc = 0.4312), and DQA1*04 (4.0 vs. 9.1, P = 0.0314, OR = 0.42, CI = 0.19-0.93, pc = 0.3454) frequencies were lower. HLA-DQB1*03 showed a tendency to protection against leprosy per se (27.3% vs. 33.7%, P = 0.0684).
###end p 36
###begin p 37
###xml 43 50 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Frequencies of HLA-DRB1 alleles in leprosy per se patients and control group
###end p 37
###begin p 38
###xml 48 50 48 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
N: number of individuals. n: number of alleles. P : probability. OR: odds ratio. CI: confidence interval. *pc: 0.13.
###end p 38
###begin p 39
###xml 50 57 50 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Frequencies of HLA-DQA1 e DQB1 alleles in leprosy per se patients and control group
###end p 39
###begin p 40
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
N: number of individuals. n: number of alleles. P: probability. OR: odds ratio. CI: confidence interval. *pc: 0.4312. **pc: 0.3454. ***pc: 0.4664.
###end p 40
###begin title 41
###xml 18 20 18 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
Leprosy subgroups vs. control group
###end title 41
###begin p 42
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 253 255 253 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 263 265 263 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 367 369 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 377 379 377 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 616 618 616 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 626 628 626 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 705 707 705 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 716 718 716 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 777 779 777 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 788 790 788 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 846 848 846 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 857 859 857 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
###xml 925 933 <span type="species:ncbi:9606">patients</span>
Table 3 shows the significant differences in HLA frequencies between the control group and the LL, Borderline, and TT leprosy subtype patients. There were differences in allelic frequencies between LL patients and the control group: while DRB1*16 (7.9% vs. 3.2%, P = 0.0405, OR = 2.59, CI = 1.12-5.97) was associated with susceptibility to the LL form, DRB1*04 (3.2% vs. 9.7%, P = 0.0165, OR = 0.31, CI = 0.11-0.87) was associated with protection against it. On further, high-resolution, analysis of the DRB1*04 and DRB1*16 alleles, only DRB1*1602 frequency was higher in LL patients than in the control group (4.8% vs. 1.2%, P = 0.0197, OR = 4.29, CI = 1.29-14.30). HLA-DQA1*03 frequency was lower (3.8% vs. 11.5%, P = 0.0184, OR = 0.25, CI = 0.07-0.87), while DQA1*05 (32.5% vs. 20.9%, P = 0.0220, OR = 2.38, CI = 1.17-4.86) and DQB1*02 (27.5% vs. 15.8%, P = 0.0103, OR = 2.59, CI = 1.29-5.1) frequencies were higher in LL patients compared to the control group.
###end p 42
###begin p 43
Frequencies of HLA class II alleles in leprosy subgroups and control group
###end p 43
###begin p 44
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
N: number of individuals. n: number of alleles. P: probability. OR: odds ratio. CI: confidence interval. *pc: 0.0208.
###end p 44
###begin p 45
###xml 17 19 17 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 27 29 27 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 85 87 85 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 95 97 95 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 307 309 307 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 317 319 317 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 458 460 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 468 470 468 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
HLA-DRB1*09 (6.8 vs. 1.6%, P = 0.0112, OR = 4.74, CI = 1.51-14.87) and DRB1*16 (9.0% vs. 3.2%, P = 0.0175, OR = 3.22, CI = 1.26-8.23) frequencies were higher in Borderline patients than in the control group. On further, high-resolution, analysis, only DRB1*1601 frequency was higher in these patients (9.0% vs. 1.8%, P = 0.0016, OR = 5.81, CI = 2.05-16.46, pc = 0.0208). HLA-DQA1*04 frequency was lower in Borderline patients than in the control group (1.7% vs. 9.1%, P = 0.0337, OR = 0.15, CI = 0.02-1.11).
###end p 45
###begin p 46
###xml 164 166 164 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 174 176 174 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 269 271 269 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 280 282 280 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 359 361 359 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 369 371 369 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
In patients with TT leprosy, although DRB1*16 frequency was not different to that of the control group, the DRB1*1602 allele frequency was found to be higher (4.4% vs. 1.1%, P = 0.0498, OR = 4.14, CI = 1.07-16.06). Furthermore, HLA- DQA1*05 frequency was higher (37.5% vs. 20.9%, P = 0.0046, OR = 3.85, CI = 1.46-10.15), while DQA1*02 frequency was lower (0% vs. 7.5%, P = 0.0298, OR = 0.23, CI = 0.03-1.80) in these patients.
###end p 46
###begin title 47
###xml 20 22 20 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
Lepromatous leprosy vs. Tuberculoid leprosy
###end title 47
###begin p 48
###xml 53 55 53 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 120 122 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 131 133 131 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 311 313 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 321 323 321 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 458 460 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 468 470 468 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
When comparing the opposite poles of the disease (LL vs. TT) (Table 4), a difference was observed for HLA-DRB1*04 (3.2% vs. 12.8%; P = 0.0090; OR = 0.20; CI = 0.06-0.67, pc = 0.117), which was associated with protection against the LL form. HLA-DRB1*08 was associated with a predisposition to LL leprosy (11.2% vs. 1.2%; P = 0.0037; OR = 12.00; CI = 1.51 - 95.12, pc = 0.0481), and HLA-DRB1*14 showed a tendency towards association with these patients (1.5% vs. 6.9%; P = 0.0595).
###end p 48
###begin p 49
###xml 77 85 <span type="species:ncbi:9606">patients</span>
HLA-DRB1 allele frequencies in Lepromatous (LL) and Tuberculoid (TT) leprosy patients
###end p 49
###begin p 50
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
N: number of individuals. n: number of alleles. P: probability. OR: odds ratio. CI: confidence interval. * pc: 0.117. **pc: 0.0481.
###end p 50
###begin p 51
No statistically significant difference in the allele frequency distributions was observed between LL and TT forms for HLA-DQA and DQB alleles (data not shown).
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
This case-control study investigated the genetic variation present in HLA-DRB1, DQA1 and DQB1 genes, and its relation to leprosy in Southern Brazil.
###end p 53
###begin p 54
###xml 23 32 23 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. leprae</italic>
###xml 213 223 213 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M. leprae </italic>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 23 32 <span type="species:ncbi:1769">M. leprae</span>
###xml 213 222 <span type="species:ncbi:1769">M. leprae</span>
###xml 684 692 <span type="species:ncbi:9606">patients</span>
In infection caused by M. leprae, HLA alleles influence not only susceptibility or resistance to the disease, but also the course of the disease. The main role of HLA molecules is to present peptides derived from M. leprae to the T cells of the host. Susceptibility to an infectious disease may be due to imperfections in some stages of this system. An individual that has a particular combination of HLA alleles that are not linked to the peptide in an appropriate way, or for whom the HLA-peptide linkage does not develop a proper lymphocyte response, will be less able to resist the invasion of the infectious agent than an individual that does not have such deficiencies [21]. In patients whose HLA systems offer protection against the disease, these genes probably select and stimulate T cells that multiply and eliminate the agent with inflammatory cytokine production, or else destroy the infected cells [22].
###end p 54
###begin p 55
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Several studies identify a consistent form for the participation of HLA alleles and haplotypes, especially class II genes, as an important genetic factor associated to leprosy. The clinical manifestation of the disease depends on the type of immune response shown by the host, and exchanges between Th1 and Th2 response types may be partially controlled by a mechanism of antigen presentation involving HLA molecules [23]. In the TT form of the disease, the production of proinflammatory cytokines by Th1 cells may help in the clearance of the bacillus. However, in the LL form, the immunosuppressor cytokines produced by the Th2 response may make this response difficult.
###end p 55
###begin p 56
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 369 376 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 580 586 <span type="species:ncbi:9103">Turkey</span>
In the present study, HLA-DRB1*16, a subtype of DR2, participates as a susceptibility marker for leprosy per se, confirming previous serological results that showed an association between HLA-DR2 and leprosy per se in patients from an equivalent geographical area (South Brazil) [11]. The association of HLA-DR2 (now DRB1*15 and DRB1*16) with susceptibility to leprosy per se has been highlighted in other studies [24,25] and in LL and TT patients, compared to healthy controls, in many populations around the world (Surinam, India, Venezuela, Egypt, Chine, Japan, Korea, Mexico, Turkey, Brazil) [reviewed in [12,26]]. Associations with the class II region are thought to occur due to the class II restriction of the presentation of mycobacterial epitopes to T-helper cells.
###end p 56
###begin p 57
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 731 732 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
Rani et al. (1992), in Korean, showed positive associations of HLA-DR2 and DQ1 with LL leprosy, and DR9 and DQ7 with Borderline leprosy; and negative associations between DR4 and DQ3 and LL leprosy [7]. The present study is in accord with these results: HLA-DRB1*DR9 was associated with susceptibility to Borderline leprosy and HLA-DRB1*04 was associated with protection against LL leprosy, as a lower frequency was observed in these patients compared to in the TT group, and DQB1*03 showed a tendency towards protection. Strong linkage disequilibria, in some populations, are known to exist within the MHC (gene order: HLA-DQB1, DQA1, DRB1) [27-29]. The weak positive association of DQB1*03 with protection against leprosy (Table 2) may be due to the strong linkage disequilibrium between DRB1*04 and this DQ allele.
###end p 57
###begin p 58
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Similar results for DRB1*04 were reported by Joko et al. (2000) for leprosy per se in a Japanese population [30] and, more recently, by both Vanderborght et al. (2007) in both Brazilian and Vietnamese populations [14] and Motta et al. (2007) in an Argentinean population [31].
###end p 58
###begin p 59
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
In addition, according to the data of the present study, HLA-DRB1*08 frequency was higher in lepromatous patients than tuberculoid patients, indicating a role in susceptibility to the most severe form of leprosy.
###end p 59
###begin p 60
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 440 448 <span type="species:ncbi:9606">patients</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
Rani et al. (1993) found a significantly higher frequency of DQB1*0601 in leprosy patients than in healthy controls, while DQA1*0103 was most frequent in LL patients and DQA1*0102 was selectively higher in borderline lepromatous patients [32]. On the other hand, DRB1*0701, DQB1*0201 and DQA1*0201 frequencies were all lower in multibacillary leprosy patients compared to TT patients and controls, and DQB1*0503 was selectively lower in TT patients. In the present study, HLA-DQA1*05 frequency was significantly higher in leprosy patients, while DQA1*02 and *04 frequencies were lower.
###end p 60
###begin p 61
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 199 205 199 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">locus </italic>
###xml 340 347 340 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se </italic>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
An unrelated genome-wide scan in 71 multi-case families from Brazil found chromosome region 6p21 (lod = 3.23) to be weakly linked to leprosy [33]. More detailed analysis indicated that more than one locus in each of these dense immune-response gene regions might affect susceptibility to leprosy, including genes that contribute to leprosy per se and to lepromatous, as opposed to tuberculoid, disease subtypes [13]. Early candidate-gene analysis, usually involving the HLA region on chromosome 6p21, has provided the first experimental evidence for the complex nature of the genetic variations involved in host genetic susceptibility to leprosy. It is therefore necessary that research be continued via a study with a larger number of patients in each group in order to verify the genes that are possibly related to protection against and susceptibility to leprosy, and to disease progression, in this Brazilian population.
###end p 61
###begin title 62
Conclusion
###end title 62
###begin p 63
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 522 528 522 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">locus </italic>
Although there was great genotypic variety in the Brazilian population, the results of the present study confirm the significant participation of HLA-DR2 (DRB1*16) and DQA1 in susceptibility to leprosy per se, and the participation of HLA-DRB1*04 in protection and of DRB1*08 in susceptibility to the severe form of the disease (lepromatous leprosy). Therefore, HLA-DRB1*1601 was associated with susceptibility to Borderline leprosy. Taken together, these HLA analyses suggest the possibility of there being more than one locus of leprosy susceptibility in the MHC.
###end p 63
###begin title 64
Competing interests
###end title 64
###begin p 65
The authors declare that they have no competing interests.
###end p 65
###begin title 66
Authors' contributions
###end title 66
###begin p 67
PSM, SAS and PGR carried out the molecular genetic studies. PSM participated in the design of the study. JELV, PSM and AMS performed the statistical analysis. JELV conceived of the study, and participated in its design and coordination and helped to draft the manuscript. PRP participated in the clinical diagnostic of leprosy. All authors read and approved the final manuscript.
###end p 67
###begin title 68
Pre-publication history
###end title 68
###begin p 69
The pre-publication history for this paper can be accessed here:
###end p 69
###begin p 70

###end p 70
###begin title 71
Acknowledgements
###end title 71
###begin p 72
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
The authors are thankful to healthy controls and patients that took part on this study, to nurses Maria Lucia Ribas and Maria Aparecida da Silva for their collaboration in collecting patients' data, as well as Fabiano Cavalcante de Melo and Marco Antonio Braga for the technical procedures performed. This study was supported in part by Laboratorio de Imunogenetica/UEM, CNPq (Brazilian Ministry of Science and Technology), Fundacao Araucaria (Government of Parana) and the Brazilian Ministry of Health. The manuscript was linguistically revised by Peter Grimshaw.
###end p 72
###begin article-title 73
###xml 0 15 <span type="species:ncbi:1769">Bacillus leprae</span>
Bacillus leprae
###end article-title 73
###begin article-title 74
Leprosy
###end article-title 74
###begin article-title 75
World Health Organization: Global leprosy situation
###end article-title 75
###begin article-title 76
Genetic dissection of immunity in leprosy
###end article-title 76
###begin article-title 77
Genetics of susceptibility to infectious diseases: tuberculosis and leprosy as examples
###end article-title 77
###begin article-title 78
The biochemistry and cell biology of antigen processing and presentation
###end article-title 78
###begin article-title 79
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
Do human leukocyte antigens have a role to play in differential manifestation of multibacillary leprosy? A study on multibacillary leprosy patients from North India
###end article-title 79
###begin article-title 80
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Novel HLA class I alleles associated with Indian leprosy patients
###end article-title 80
###begin article-title 81
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Analysis of the immunogenetic background of Japanese leprosy patients by the HLA systems
###end article-title 81
###begin article-title 82
Leprosy associated with HLA-DR2 and DQw1 in the population of Northern Thailand
###end article-title 82
###begin article-title 83
Association of leprosy with HLA-DR2 in a Southern Brazilian population
###end article-title 83
###begin article-title 84
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leukocyte antigens in tuberculosis and leprosy
###end article-title 84
###begin article-title 85
Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes
###end article-title 85
###begin article-title 86
###xml 125 133 <span type="species:ncbi:9606">patients</span>
HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients
###end article-title 86
###begin article-title 87
An epidemiologist's view of leprosy
###end article-title 87
###begin article-title 88
HLA polymorphism and evaluation of European, African, and Amerindian contribution to the white and mulatto populations from Parana, Brazil
###end article-title 88
###begin article-title 89
Color and genomic ancestry in Brazilians
###end article-title 89
###begin article-title 90
HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours; An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
###end article-title 90
###begin article-title 91
Tipagem HLA-DQA e HLA-DQB por biologia molecular PCR-SSP, Media resolucao
###end article-title 91
###begin article-title 92
Arlequin ver. 3.0: An integrated software package for population genetics data analysis
###end article-title 92
###begin article-title 93
The HLA System: Second of Two Parts
###end article-title 93
###begin article-title 94
###xml 37 55 37 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Toxoplasma gondii </italic>
###xml 37 54 <span type="species:ncbi:5811">Toxoplasma gondii</span>
HLA-class II genes modify outcome of Toxoplasma gondii infection
###end article-title 94
###begin article-title 95
Genetic host resistance and susceptibility to leprosy
###end article-title 95
###begin article-title 96
HLA and leprosy in Koreans
###end article-title 96
###begin article-title 97
Leprosy in a high-prevalence Egyptian village: epidemiology and risk factors
###end article-title 97
###begin article-title 98
Molecular mechanisms of MHC linked susceptibility in leprosy: towards the development of synthetic vaccines
###end article-title 98
###begin article-title 99
###xml 21 26 <span type="species:ncbi:9606">human</span>
Associations between human leukocyte antigens and leprosy in the Turkish population
###end article-title 99
###begin article-title 100
HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China
###end article-title 100
###begin article-title 101
Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population
###end article-title 101
###begin article-title 102
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Human leukocyte antigens in forms of leprosy among Japanese patients
###end article-title 102
###begin article-title 103
Role of HLA-DR and HLA-DQ alleles in multibacillary leprosy and paucibacillary leprosy in the province of Chaco (Argentina)
###end article-title 103
###begin article-title 104
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Study of HLA class II alleles by PCR oligotyping in leprosy patients from north India
###end article-title 104
###begin article-title 105
Genome-wide scans for leprosy and tuberculosis susceptibility genes in Brazilians
###end article-title 105

